Literature DB >> 20030429

Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Diya F Mutasim1.   

Abstract

Elderly individuals are susceptible to autoimmune bullous dermatoses (ABDs), which may be associated with high morbidity and mortality. ABDs result from an autoimmune response to components of the basement membrane zone at the dermal-epidermal junction or desmosomes. Bullous pemphigoid results from autoimmunity to hemidesmosomal proteins present in the basement membrane of stratified squamous epithelia. Patients present with tense blisters in flexural areas of the skin. Mild disease may be treated with potent topical corticosteroids, while extensive disease usually requires systemic corticosteroids or systemic immunosuppressive agents such as azathioprine. Mucosal pemphigoid affects one or more mucous membranes that are lined by stratified squamous epithelia. The two most commonly involved sites are the eye and the oral cavity. Lesions frequently result in scar formation that may cause blindness. Patients with severe disease or ocular involvement require aggressive therapy with corticosteroids and cyclophosphamide. Epidermolysis bullosa acquisita results from autoimmunity to type VII collagen in the anchoring fibrils of the basement membrane. Lesions may either arise on an inflammatory base or be non-inflammatory and result primarily from trauma. Treatment options include corticosteroids, dapsone, ciclosporin, methotrexate and plasmapheresis/immunoapheresis. Paraneoplastic pemphigus results from autoimmunity to multiple desmosomal antigens. The disorder is associated with neoplasms, especially leukaemia, lymphoma and thymoma. Patients present with stomatitis and polymorphous skin eruption. The disease may respond to successful treatment of the underlying neoplasm or may require immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20030429     DOI: 10.2165/11318600-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  124 in total

Review 1.  Emerging treatment for epidermolysis bullosa acquisita.

Authors:  L Engineer; A R Ahmed
Journal:  J Am Acad Dermatol       Date:  2001-05       Impact factor: 11.527

2.  Benign mucous membrane pemphigoid. Response to therapy with cyclophosphamide.

Authors:  H J Brody; D J Pirozzi
Journal:  Arch Dermatol       Date:  1977-11

3.  Benign mucous membrane pemphigoid. An unusual case with electron microscopic findings.

Authors:  G J Brauner; K Jimbow
Journal:  Arch Dermatol       Date:  1972-10

4.  Minimizing cicatricial pemphigoid orodynia with minocycline.

Authors:  L Poskitt; F Wojnarowska
Journal:  Br J Dermatol       Date:  1995-05       Impact factor: 9.302

Review 5.  Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion.

Authors:  J R Stanley
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

Review 6.  Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.

Authors:  Hanadi Kazkaz; David Isenberg
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

Review 7.  Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations.

Authors:  J R Person; R S Rogers
Journal:  Mayo Clin Proc       Date:  1977-01       Impact factor: 7.616

8.  Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study.

Authors:  V A Venning; P A Frith; A J Bron; P R Millard; F Wojnarowska
Journal:  Br J Dermatol       Date:  1988-01       Impact factor: 9.302

9.  Epidermolysis bullosa acquisita--successful treatment with colchicine.

Authors:  M Megahed; K Scharffetter-Kochanek
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

10.  Azathioprine in treatment of bullous pemphigoid.

Authors:  M W Greaves; J L Burton; J Marks; R P Dawber
Journal:  Br Med J       Date:  1971-01-16
View more
  2 in total

Review 1.  Thymoma and autoimmunity.

Authors:  Shahar Shelly; Nancy Agmon-Levin; Arie Altman; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

2.  Epidermolysis bullosa acquisita.

Authors:  Denise Miyamoto; Juliana Olivieri Gordilho; Claudia Giuli Santi; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-06-11       Impact factor: 2.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.